

**Anti-CXCL4 / PF4 Reference Antibody (U.Penn. patent anti-PF4)  
Recombinant Antibody  
Catalog # APR10872****Specification**

---

**Anti-CXCL4 / PF4 Reference Antibody (U.Penn. patent anti-PF4) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">P02776</a>
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	144.5 KDa

**Anti-CXCL4 / PF4 Reference Antibody (U.Penn. patent anti-PF4) - Additional Information****Target/Specificity**

CXCL4 / PF4

**Endotoxin**

&lt; 0.001EU/ µg, determined by LAL method.

**Conjugation**

Unconjugated

**Expression system**

CHO Cell

**Format**

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

**Anti-CXCL4 / PF4 Reference Antibody (U.Penn. patent anti-PF4) - Protein Information****Name** PF4**Synonyms** CXCL4, SCYB4**Function**

Chemokine released during platelet aggregation that plays a role in different biological processes including hematopoiesis, cell proliferation, differentiation, and activation (PubMed:<a href="http://www.uniprot.org/citations/9531587" target="\_blank">9531587</a>, PubMed:<a href="http://www.uniprot.org/citations/29930254" target="\_blank">29930254</a>). Acts via different functional receptors including CCR1, CXCR3A or CXCR3B (PubMed:<a href="http://www.uniprot.org/citations/18174362" target="\_blank">18174362</a>, PubMed:<a href="http://www.uniprot.org/citations/29930254" target="\_blank">29930254</a>). Upon interaction with CXCR3A receptor, induces activated T-lymphocytes migration mediated via downstream Ras/extracellular signal-regulated kinase (ERK) signaling (PubMed:<a href="http://www.uniprot.org/citations/18174362" target="\_blank">18174362</a>, PubMed:<a href="http://www.uniprot.org/citations/18174362" target="\_blank">18174362</a>, PubMed:<a href="http://www.uniprot.org/citations/18174362" target="\_blank">18174362</a>).

<http://www.uniprot.org/citations/24469069> target="\_blank">24469069</a>). Neutralizes the anticoagulant effect of heparin by binding more strongly to heparin than to the chondroitin-4-sulfate chains of the carrier molecule. Plays a role in the inhibition of hematopoiesis and in the maintenance of hematopoietic stem cell (HSC) quiescence (PubMed:<a href="http://www.uniprot.org/citations/9531587">http://www.uniprot.org/citations/9531587 target="\_blank">9531587</a>). Chemotactic for neutrophils and monocytes via CCR1 (PubMed:<a href="http://www.uniprot.org/citations/29930254">http://www.uniprot.org/citations/29930254 target="\_blank">29930254</a>). Inhibits endothelial cell proliferation. In cooperation with toll-like receptor 8/TLR8, induces chromatin remodeling and activates inflammatory gene expression via the TBK1-IRF5 axis (PubMed:<a href="http://www.uniprot.org/citations/35701499">http://www.uniprot.org/citations/35701499 target="\_blank">35701499</a>). In addition, induces myofibroblast differentiation and collagen synthesis in different precursor cells, including endothelial cells, by stimulating endothelial-to-mesenchymal transition (PubMed:<a href="http://www.uniprot.org/citations/34986347">http://www.uniprot.org/citations/34986347 target="\_blank">34986347</a>).

### Cellular Location


Secreted.

### Anti-CXCL4 / PF4 Reference Antibody (U.Penn. patent anti-PF4) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### Anti-CXCL4 / PF4 Reference Antibody (U.Penn. patent anti-PF4) - Images



Anti-CXCL4 / PF4 Reference Antibody (U.Penn. patent anti-PF4) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-CXCL4 / PF4 Reference Antibody (U.Penn. patent anti-PF4) is more than 95% ,determined by SEC-HPLC.